Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

20181,264 citationsJournal Articlebronze Open Access

Authors

Nicholas C. Turner · Royal Marsden Hospital

Dennis J. Slamon · University of California, Los Angeles

Jungsil Ro · National Cancer Center

Igor Bondarenko · Dnipro State Medical University

Seock‐Ah Im · National University College

Norikazu Masuda · Osaka National Hospital

Marco Colleoni

Abstract

Among patients with hormone-receptor-positive, HER2-negative advanced breast cancer who had sensitivity to previous endocrine therapy, treatment with palbociclib-fulvestrant resulted in longer overall survival than treatment with placebo-fulvestrant. The differences in overall survival in the entire trial group were not significant. (Funded by Pfizer; PALOMA-3 ClinicalTrials.gov number, NCT01942135 .).

Topics & Keywords

Advanced Breast Cancer Therapies HER2/EGFR in Cancer Research Cancer-related Molecular Pathways

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 379, Issue 20, pp. 1926-1936

DOI: 10.1056/nejmoa1810527

Field-Weighted Citation Impact: 92.02